A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects
The trial is a single arm, single-center, non-randomized phase I clinical trial which is designed to evaluate the safety and efficacy of C-CAR039 in treatment of relapsed or refractory NHL patients
Non-Hodgkin's B-cell Lymphoma
BIOLOGICAL: Prizloncabtagene Autoleucel
Incidence and severity of adverse events, Incidence and severity of adverse events after CAR-T infusion, Up to 12 weeks after C-CAR039 infusion
Overall Response rate (ORR), Complete response (CR) rate plus partial response (PR) rate by Lugano 2014 criteria, Up to 24 Months after C-CAR039 infusion|Duration of response (DOR), The time from the date of first response (PR or CR) to the date of disease progression or death after C-CAR039 infusion, Up to 24 Months after C-CAR039 infusion|Progression-free survival (PFS), The time from C-CAR039 infusion to the date of progression as assessed by Lugano 2014 criteria or death, Up to 24 Months after C-CAR039 infusion|Overall survival (OS), The time from C-CAR039 infusion to the date of death, Up to 24 Months after C-CAR039 infusion
This study plans to enroll 25 patients to assess the safety and efficacy of C-CAR039. Subjects who meet the eligibility criteria will receive a single dose of C-CAR039 injection.

The study will include the following sequential phases: Screening, Apheresis and C-CAR039 manufacturing, Bridging (if needed), Baseline, lymphodepletion, C-CAR039 infusion, and Follow-up Visit.